Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
The ninth acquisition since 2018
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Subscribe To Our Newsletter & Stay Updated
